Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use
Authors:
- 14 February 2025
- journal article
- review article
- Published by Elsevier in Journal of Cardiology
- Vol. 85 (6) , 473-479
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Therapeutic Potential of FXI Inhibitors: Hype or Hope?Drugs, 2024
- Factor XI Inhibitors: A New Horizon in Anticoagulation TherapyCardiology and Therapy, 2024
- Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke PreventionJournal of Stroke and Cerebrovascular Diseases, 2022
- Factor XI Inhibition to Uncouple Thrombosis From HemostasisJACC, 2021
- Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral AnticoagulantsJACC, 2021
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XIJournal of Molecular Biology, 2019
- BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokineticsResearch and Practice in Thrombosis and Haemostasis, 2019
- Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III TrialsEuropean Journal of Vascular and Endovascular Surgery, 2014
- Factor XI: Hemostasis, Thrombosis, and AntithrombosisThrombosis Research, 2012